Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.
<table>
<thead>
<tr>
<th>Key to abbreviations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DOR</strong></td>
</tr>
<tr>
<td>Dapivirine (Vistaril®)</td>
</tr>
<tr>
<td>Rilpivirine (Edurado®)</td>
</tr>
<tr>
<td>Abacavir + lamivudine + tenofovir (Delstrigo®)</td>
</tr>
<tr>
<td>Abacavir + lamivudine + tenofovir (Tivicay®)</td>
</tr>
<tr>
<td>EFV = Efavirenz (Rilpinc®)</td>
</tr>
<tr>
<td>Ritonavir (Norvir®)</td>
</tr>
<tr>
<td>TDF = Tenofovir (Viread®)</td>
</tr>
</tbody>
</table>

**Key to symbols**
- These drugs should not be coadministered
- Potential interaction — may require close monitoring, alteration of drug dosage or timing of administration
- Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
- No clinically significant interaction expected

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious option.
Antivirals

- Adefovir
- Emtricitabine
- Efavirenz
- Indinavir
- Lamivudine
- Nelfinavir
- Nevirapine
- Zidovudine

Calcium Channel Blockers

- Amlodipine
- Dilazep
- Felodipine
- Nifedipine
- Nicardipine
- Verapamil

Cancer Therapies

- Asparaginase
- Bevacizumab
- Bleomycin
- Cisplatin
- Cytarabine
- Darbepoetin
- Daclatasvir
- Dabrafenib
- Dacomitinib
- Daunorubicin
- Docetaxel
- Doxorubicin
- Drotrecogin alfa (activated)
- Erlotinib
- Etoposide
- Eribulin
- Everolimus
- Exemestane
- Fludarabine
- Fluorouracil
- Formestane
- Gefitinib
- Gemcitabine
- Gefitinib
- Glatiramer acetate
- Gossypol
- Gatifloxacin
- Glatiramer acetate
- Gilteritinib
- Gilivirin
- Glucocorticoids
- Glimeride
- Glimepiride
- Glipizide
- Glipizide
- Goserelin
- Glatiramer acetate
- Gilteritinib
- Goserelin
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetron
- Granisetro
### Key to abbreviations

<table>
<thead>
<tr>
<th>DOR</th>
<th>NVP</th>
<th>RTV</th>
<th>ETR</th>
<th>TP</th>
<th>FATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOR+</td>
<td>NVP+</td>
<td>RTV+</td>
<td>ETR+</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Key to symbols**

- **●** These drugs should not be coadministered
- **▲** Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
- **▲▲** Potential interaction likely to be of weak intensity. Additional action monitoring or dosage adjustment is unlikely to be required
- **▲▲▲** No clinically significant interaction expected

---

#### Erection Dysfunction Agents

- **Avanafil**
- **Stadial (Erection Dysfunction)**
- **Tadalafil (Erection Dysfunction)**
- **Vardenafil**

#### Gastrointestinal Agents

- **Alseron**
- **Antacids**
- **Bisacodyl**
- **Cimetidine**
- **Cisapride**
- **Domperidone**
- **Dombranil**
- **Graniten**
- **Metoclopramide**
- **Ondarsen**
- **Proktroprione**

#### Herbas/Supplements/Vitamins

- **African potato**
- **Aloe vera**
- **Ascorbic Acid (vitamin C) (alone)**
- **Ascorbic Acid [in multivitamins]**
- **Calcium supplements**
- **Cat’s claw (Uncaria tomentosa)**
- **Colcalclerol (vitamin D3) (alone)**
- **Colcalciferol [in multivitamins]**
- **Cubeb pepper ‘Piper cubeba’**
- **Cyanocobalamin (alone)**
- **Cyanocobalamin [in multivitamins]**
- **Echinaees**
- **Eucalyptus globulus**
- **Ferrous fumarate**
- **Folic acid (alone)**
- **Garlic**
- **Ginger (Zingiber officinale)**
- **Ginkgo biloba**
- **Goldenseal root (Hydrastis canadensis)**
- **Grapefruit juice**
- **Hops (Humulus lupulus)**

---

#### Key to symbols

- **●** These drugs should not be coadministered
- **▲** Potential interaction - may require close monitoring, alteration of drug dosage or timing of administration
- **▲▲** Potential interaction likely to be of weak intensity. Additional action monitoring or dosage adjustment is unlikely to be required
- **▲▲▲** No clinically significant interaction expected

---

Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister.
We aim to ensure that information is accurate and consistent with current knowledge and practice. However, the University of Manchester does not offer or provide advice on the use of licit or illicit drugs. Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious approach that may be required. 

### Key to abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOR</td>
<td>Dolutegravir (Dorovine®)</td>
</tr>
<tr>
<td>DOR +</td>
<td>Dolutegravir + Lamivudine + Tenofovir-DF (Delzicol®)</td>
</tr>
<tr>
<td>ETR</td>
<td>Efavirenz (Etravance®)</td>
</tr>
<tr>
<td>NVP</td>
<td>Nevirapine (Viramune®)</td>
</tr>
<tr>
<td>F/TAF</td>
<td>Fosamprenavir/Sulfamethoxazole (F/Taf)</td>
</tr>
<tr>
<td>RPV</td>
<td>Raltegravir (Eduragen®)</td>
</tr>
<tr>
<td>RVF</td>
<td>Ritonavir (Norvir®)</td>
</tr>
<tr>
<td>NVP +</td>
<td>Nevirapine + Tenofovir-DF (Dovategrin®)</td>
</tr>
</tbody>
</table>
| ETR + | Efavirenz + Tenofovir-DF (Efavirone®)

### Key to symbols

- **D**: These drugs should not be coadministered
- **M**: Potential interaction may require close monitoring, alteration of drug dosage or timing of administration
- **A**: Potential interaction likely to be of weak intensity. Additional action/monitoring or dosage adjustment is unlikely to be required
- **X**: No clinically significant interaction expected

Where advice differs between countries, and/or between boosted and unboosted regimens, the charts reflect the more cautious approach that may be required.